ARCHIVES

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

This article is from The Cancer Letter archive.

Vol. 07 No. 21 | May 22, 1981

Download PDF Visit The Full Archive

Related Articles

ORI Clears Los Angeles Physician Of Misconduct In NSABP Participation

June 16, 1995

Dear FDA: Provenge Provokes Letters From Opponents, Advocates, Investors.

April 27, 2007

Clinical Education Grants Held To 170 Payline, No New Awards; Organ Site Renewals Limited To 180

March 26, 1982

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

April 9, 2010

Amgen Announces Cochrane Findings: ESAs Increase Risk Of On-Study Death.

October 3, 2008

Lung Cancer Gets Less Press, Study Finds

May 18, 2001